Year: 2025
Type: dissertation
Study design: Observational Study
Abstract: Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer death in the United States. Although overall survival-rates are improving for CRC patients, it is increasing in patients below the age of 50, indicating a need for improved knowledge in risk factors and earlier screening. In the search for CRC biomarkers, sporadic mutations are known to contribute to the majority of CRC cases, while hereditary cancer syndromes account for about 5-6%, and low-to-moderate penetrance alleles contribute to 20-30% of all cases. Transforming Growth Factor Beta (TGFβ) is a multifunctional cytokine that belongs to a family of serine-threonine receptors. TGFβ plays a multifaceted role in controlling cell growth, differentiation, extracellular matrix remodeling, and the immune response, and under normal physiological conditions TGFβ functions as a potent inhibitor cell proliferation. However, when cells reach a malignant state, TGFβ can switch to promote cell proliferation, metastasis, EMT, and immune evasion. Although there is still limited evidence for cancer-risk association in TGFβ Receptor 1 (TGFBR1) in colorectal cancer, TGFBR1 inhibitors have recently been found to be effective combinational treatment of CRC and therapeutic resistance. We are the first group to identify CRC risk-association in TGFBR1 germline variants. Specifically, we discovered that TGFBR1*6A, a common TGFBR1 polymorphism historically overlooked by next-generation sequencing because of its high GC content, is associated with a reduced risk of CRC. We conducted in vivo experiments using a novel humanized TGFBR1*6A knock-in mouse model and observed that mice carrying the TGFBR1*6A allele developed fewer and less aggressive polyps. Furthermore, analysis of cases and controls from the family-based ‘Colon Cancer Family Registry’ and adjusting for confounding factors, including genetic ancestry admixture, revealed a protective effect associated with TGFBR1*6A, which exhibited an even more pronounced effect size among siblings. Importantly, there is concordance between our animal model and human findings, and decreased risk among sibling TGFBR1*6A carriers may have clinical usefulness in families with a history of CRC.
Author: Johansen, Allan Moradkhan
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Transdisciplinary Studies of Genetic Variation in Colorectal Cancer, G2154620358, G2653101739, G6294239886, Hormones and Colon Cancer: Epigenetic Subtypes, Risk, and Survival, TGFBR1 Signaling in Colorectal Cancer, Genomic Wide Association Study of Colorectal Cancer, G804866679, G8117347302, Molecular Epidemiology of Colorectal Cancer, Colon Cancer Family Registry Cohort
OpenAlex ID: W7010030746
